{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:06:30Z","timestamp":1784099190597,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors play an important role in the treatment of breast cancer and show therapeutic potential for gastrointestinal (GI) tumors. However, their real-world GI safety profile remains incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Disproportionate reporting signals of GI adverse events (AEs) were assessed using the ROR, PRR and BCPNN algorithms, based on data from the FDA Adverse Event Reporting System database (2004-Q1 2025). Time-to-onset was analyzed using Weibull distribution, and serious vs. non-serious AE comparisons used non-parametric tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 63,722 reports were associated with CDK4\/6 inhibitors in breast cancer patients, among which 18,589 involved GI AEs. The three agents showed heterogeneous GI reporting patterns, with abdominal discomfort being the sole identified class-wide effect. Palbociclib accounted for the largest proportion of CDK4\/6 inhibitor-related GI AE reports among the three agents, and its disproportionate reporting signals primarily involved oropharyngeal and upper GI events, with lip exfoliation and tongue blistering identified as its strongest signals. Ribociclib had the highest proportion of serious GI reports among the three drugs (82.38%), with 14.25% of its reports having a fatal outcome, and showed significant disproportionality signals for reflux gastritis and dysbiosis. For abemaciclib, gastrointestinal disorders was the most frequently reported System Organ Class, and diarrhea was its strongest disproportionate reporting signal. Notably, over 80% of positive GI pharmacovigilance signals detected in this study were absent from current prescribing information. All agents exhibited an early failure-type time-to-onset profile (\u03b2 &amp;lt; 1), with a statistically significant difference in median onset time across agents: 15 days for abemaciclib, 27 days for ribociclib, and 49 days for palbociclib (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). Serious GI AEs were more frequently reported in patients with advanced age, low weight, ribociclib exposure, and concomitant therapy with aromatase inhibitors or fulvestrant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study revealed heterogeneous disproportionate reporting patterns for GI AEs among CDK4\/6 inhibitors and identified unlabeled pharmacovigilance signals. These findings are exclusively hypothesis-generating pharmacovigilance observations, not evidence of incidence, causal associations, or clinically confirmed inter-drug risk differences. The results might help prioritize drug-event pairs for further research and require validation in well-designed observational or prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1876415","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:10:36Z","timestamp":1784095836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal toxicity associated with cyclin-dependent kinase 4\/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengjiao","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tianjin Baodi Hospital, Tianjin Medical University Baodi Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Baodi Hospital, Tianjin Medical University Baodi Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Baodi Hospital, Tianjin Medical University Baodi Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Dou","sequence":"additional","affiliation":[{"name":"Network Information Center, Tianjin Baodi Hospital, Tianjin Medical University Baodi Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinguo","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tianjin Baodi Hospital, Tianjin Medical University Baodi Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B4","unstructured":"New York\n          FDA\n          IBRANCE\n          \n          2025"},{"key":"B5","unstructured":"New Jersey\n          FDA\n          FDA Approved Drug Products: KISQALI\n          \n          2024"},{"key":"B6","unstructured":"Indianapolis\n          FDA\n          FDA Approved Drug Products: VERZENIO\u2122 \n          \n          2018"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1269922","DOI":"10.3389\/fphar.2024.1269922","article-title":"The adverse events of CDK4\/6 inhibitors for HR+\/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials","volume":"15","author":"Pu","year":"2024","journal-title":"Front Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.008","article-title":"CDK4\/6 inhibitors in breast cancer therapy: Current practice and future opportunities","volume":"191","author":"Lynce","year":"2018","journal-title":"Pharmacol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1038\/s41598-024-53151-8","article-title":"Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer","volume":"14","author":"Kappel","year":"2024","journal-title":"Sci Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1113","DOI":"10.1093\/oncolo\/oyae101","article-title":"Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer","volume":"29","author":"De Sanctis","year":"2024","journal-title":"Oncologist."},{"key":"B11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.24.00511","article-title":"Cyclin-dependent kinase 4\/6 inhibition as a novel therapy for peritoneal mucinous carcinomatosis with GNAS mutations","volume":"43","author":"Weitz","year":"2025","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"105177","DOI":"10.1016\/j.ebiom.2024.105177","article-title":"Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4\/6 inhibitor therapy in oesophageal squamous cell carcinoma","volume":"105","author":"Gao","year":"2024","journal-title":"EBioMedicine."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/2042098617722516","article-title":"Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis","volume":"8","author":"Shohdy","year":"2017","journal-title":"Ther Adv Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/cpt.70180","article-title":"The rising misuse of pharmacovigilance reporting systems: a threat to evidence-based medicine","volume":"119","author":"Khouri","year":"2026","journal-title":"Clin Pharmacol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","article-title":"Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA","volume":"27","author":"Fukazawa","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","article-title":"Charting and sidestepping the pitfalls of disproportionality analysis","volume":"49","author":"Fusaroli","year":"2026","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"102086","DOI":"10.1016\/j.ctrv.2020.102086","article-title":"Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis","volume":"90","author":"Desnoyers","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e18284","DOI":"10.1200\/JCO.2017.35.15_suppl.e18284","article-title":"Risk of gastrointestinal and hepatic toxicities in patients with hormone receptor-positive HER2-negative breast cancer treated with CDK 4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Tun","year":"2017","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest New Drugs."},{"key":"B29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.18632\/oncotarget.28249","article-title":"Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation","volume":"13","author":"Torres-Guzman","year":"2022","journal-title":"Oncotarget."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1747-1028-6-3","article-title":"Efficient Wnt mediated intestinal hyperproliferation requires the cyclin D2-CDK4\/6 complex","volume":"6","author":"Myant","year":"2011","journal-title":"Cell Div."},{"key":"B31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.20892\/j.issn.2095-3941.2018.0257","article-title":"Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance","volume":"16","author":"Zainal","year":"2019","journal-title":"Cancer Biol Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jfma.2020.12.009","article-title":"Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma","volume":"120","author":"Wang","year":"2021","journal-title":"J Formos Med Assoc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1080\/15384101.2023.2217003","article-title":"CDK4\/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan","volume":"22","author":"Blume","year":"2023","journal-title":"Cell Cycle."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","article-title":"Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies","volume":"22","author":"Hu","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/path.6078","article-title":"CDK4\/6 inhibitor modulating active and quiescent intestinal stem cells for prevention of chemotherapy-induced diarrhea","volume":"260","author":"Xiang","year":"2023","journal-title":"J Pathol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR(+)\/HER2(-) Breast Cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"35226","DOI":"10.18632\/oncotarget.26215","article-title":"The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget."},{"key":"B38","doi-asserted-by":"publisher","first-page":"C1193","DOI":"10.1152\/ajpcell.1998.275.5.C1193","article-title":"Caco-2 intestinal cell differentiation is associated with G1 arrest and suppression of CDK2 and CDK4","volume":"275","author":"Ding","year":"1998","journal-title":"Am J Physiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1042\/BJ20061436","article-title":"Induced JunD in intestinal epithelial cells represses CDK4 transcription through its proximal promoter region following polyamine depletion","volume":"403","author":"Xiao","year":"2007","journal-title":"Biochem J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal Toxicity in Rats Following Administration of CDK4\/6 Inhibitors Is Independent of Primary Pharmacology","volume":"18","author":"Thibault","year":"2019","journal-title":"Mol Cancer Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.18735","article-title":"Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells","volume":"201","author":"Xie","year":"2023","journal-title":"Br J Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.abb.2011.03.009","article-title":"Regulation of gastrointestinal motility by Ca2+\/calmodulin-stimulated protein kinase II","volume":"510","author":"Perrino","year":"2011","journal-title":"Arch Biochem Biophys."},{"key":"B43","doi-asserted-by":"publisher","first-page":"eabq7839","DOI":"10.1126\/scitranslmed.abq7839","article-title":"An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor","volume":"15","author":"Reyes Gaido","year":"2023","journal-title":"Sci Transl Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/ijc.35255","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and cardiotoxic events in breast cancer: a pharmacovigilance study based on the FAERS database","volume":"156","author":"Li","year":"2025","journal-title":"Int J Cancer."},{"key":"B45","unstructured":"Drug development and drug interactions: Table of substrates, inhibitors and inducers"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1876415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:10:38Z","timestamp":1784095838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1876415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":45,"alternative-id":["10.3389\/fmed.2026.1876415"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1876415","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1876415"}}